|
1
|
Jin Y, Zhou P, Huang S, Shao C, Huang D, Su X, Yang R, Jiang J, Wu J. Cucurbitacin B Inhibits the Proliferation of WPMY-1 Cells and HPRF Cells via the p53/MDM2 Axis. Int J Mol Sci 2024; 25:9333. [PMID: 39273281 PMCID: PMC11395236 DOI: 10.3390/ijms25179333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2024] [Revised: 08/23/2024] [Accepted: 08/26/2024] [Indexed: 09/15/2024] Open
Abstract
Modern research has shown that Cucurbitacin B (Cu B) possesses various biological activities such as liver protection, anti-inflammatory, and anti-tumor effects. However, the majority of research has primarily concentrated on its hepatoprotective effects, with limited attention devoted to exploring its potential impact on the prostate. Our research indicates that Cu B effectively inhibits the proliferation of human prostate stromal cells (WPMY-1) and fibroblasts (HPRF), while triggering apoptosis in prostate cells. When treated with 100 nM Cu B, the apoptosis rates of WPMY-1 and HPRF cells reached 51.73 ± 5.38% and 26.83 ± 0.40%, respectively. In addition, the cell cycle assay showed that Cu B had a G2/M phase cycle arrest effect on WPMY-1 cells. Based on RNA-sequencing analysis, Cu B might inhibit prostate cell proliferation via the p53 signaling pathway. Subsequently, the related gene and protein expression levels were measured using quantitative real-time PCR (RT-qPCR), immunocytochemistry (ICC), and enzyme-linked immunosorbent assays (ELISA). Our results mirrored the regulation of tumor protein p53 (TP53), mouse double minute-2 (MDM2), cyclin D1 (CCND1), and thrombospondin 1 (THBS1) in Cu B-induced prostate cell apoptosis. Altogether, Cu B may inhibit prostate cell proliferation and correlate to the modulation of the p53/MDM2 signaling cascade.
Collapse
Affiliation(s)
- Yangtao Jin
- NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School, Fudan University, Shanghai 200237, China; (Y.J.); (P.Z.); (S.H.); (C.S.); (D.H.); (X.S.); (R.Y.); (J.J.)
- Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China
| | - Ping Zhou
- NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School, Fudan University, Shanghai 200237, China; (Y.J.); (P.Z.); (S.H.); (C.S.); (D.H.); (X.S.); (R.Y.); (J.J.)
- Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China
| | - Sisi Huang
- NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School, Fudan University, Shanghai 200237, China; (Y.J.); (P.Z.); (S.H.); (C.S.); (D.H.); (X.S.); (R.Y.); (J.J.)
- Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China
| | - Congcong Shao
- NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School, Fudan University, Shanghai 200237, China; (Y.J.); (P.Z.); (S.H.); (C.S.); (D.H.); (X.S.); (R.Y.); (J.J.)
- Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China
| | - Dongyan Huang
- NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School, Fudan University, Shanghai 200237, China; (Y.J.); (P.Z.); (S.H.); (C.S.); (D.H.); (X.S.); (R.Y.); (J.J.)
- Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China
| | - Xin Su
- NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School, Fudan University, Shanghai 200237, China; (Y.J.); (P.Z.); (S.H.); (C.S.); (D.H.); (X.S.); (R.Y.); (J.J.)
- Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China
| | - Rongfu Yang
- NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School, Fudan University, Shanghai 200237, China; (Y.J.); (P.Z.); (S.H.); (C.S.); (D.H.); (X.S.); (R.Y.); (J.J.)
- Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China
| | - Juan Jiang
- NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School, Fudan University, Shanghai 200237, China; (Y.J.); (P.Z.); (S.H.); (C.S.); (D.H.); (X.S.); (R.Y.); (J.J.)
- Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China
| | - Jianhui Wu
- NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School, Fudan University, Shanghai 200237, China; (Y.J.); (P.Z.); (S.H.); (C.S.); (D.H.); (X.S.); (R.Y.); (J.J.)
- Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China
| |
Collapse
|
|
2
|
Successful treatment of complicated benign prostatic hyperplasia in a diabetic patient with water vapor thermal therapy and urethral stenting. Urol Case Rep 2019; 26:100921. [PMID: 31467853 PMCID: PMC6712284 DOI: 10.1016/j.eucr.2019.100921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2019] [Accepted: 05/21/2019] [Indexed: 11/22/2022] Open
Abstract
Water Vapor Thermal Therapy is a novel, office-based procedure which has gained traction as first line therapy in specific therapeutic cases of benign prostatic hyperplasia. In this study, we present a case of a diabetic patient with complicated benign prostatic hyperplasia who presented with acute urinary retention along with bilateral hydronephrosis and acute kidney injury. He was treated with water vapor thermal therapy and subsequent urethral stenting, which alleviated his acute presentation and clinical symptoms. To the authors' knowledge, there are no reported cases which highlight the use of water vapor thermal therapy in complicated benign prostatic hyperplasia.
Collapse
|
|
3
|
Fonseca J, Martins da Silva C. The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia by primary care family physicians in Portugal. Clin Drug Investig 2015; 35 Suppl 1:19-27. [PMID: 25708607 DOI: 10.1007/s40261-014-0256-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND The shift towards primarily pharmacological management of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) has led to an increasing proportion of patients being treated in the primary care setting. METHOD Two related studies were undertaken in Portugal. The first was a survey of primary care family physicians regarding the management of LUTS/BPH. The second was a cross-sectional study of the records of patients with suspected or confirmed LUTS/BPH managed by the surveyed physicians. RESULTS One hundred and sixty-three physicians were surveyed between 16 June 2012 and 10 February 2013 and 2,988 patients were identified (mean age 68 years). While 80 % of physicians would order diagnostic tests for patients reporting symptoms, only 2.5 % would initiate treatment based on reported symptoms alone. Only 1 % would refer patients directly to a urologist for diagnosis, and 75 % would only refer patients after an inadequate response to treatment in the primary care setting. Management practices varied according to physicians' age and experience. Nocturia was both the most common and the most bothersome symptom. Erectile dysfunction was reported by 51 % of patients and 81 % had hypertension, hypercholesterolaemia and/or diabetes mellitus. Diagnosis and treatment of LUTS/BPH differed for older patients, those with comorbidities and those with more severe nocturia at presentation. CONCLUSION Primary care physicians in Portugal usually diagnose and treat patients with LUTS/BPH rather than refer them to a urologist. Physicians' age and experience, and patients' age, comorbidities and symptom severity affect the management of LUTS/BPH in primary care in Portugal.
Collapse
Affiliation(s)
- Júlio Fonseca
- Department of Urology, Hospital Beatriz Angelo, Loures, Portugal
| | | |
Collapse
|